Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 20;9(1):e27.
doi: 10.1002/vro2.27. eCollection 2022 Dec.

Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009-2019)

Sabina Sheppard-Olivares  1   2 , Nora M Bello  3 , Chad M Johannes  4 , Samuel E Hocker  5   6 , Barbara Biller  7   8 , Brian Husbands  9   10 , Elizabeth Snyder  11   12 , Mattison McMillan  13   14 , Talon McKee  15 , Raelene M Wouda  1
Affiliations

Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009-2019)

Sabina Sheppard-Olivares et al. Vet Rec Open. .

Abstract

Background: Insulinomas are the most common tumour of the endocrine pancreas in dogs. These malignant tumours have a high metastatic rate and limited chemotherapeutic options. The multi-receptor tyrosine kinase inhibitor sunitinib malate has benefit in the treatment of metastatic insulinoma in people. Toceranib phosphate, an analogous veterinary agent, may provide benefit for dogs.

Methods: A retrospective study describing the extent and duration of clinical outcomes and adverse events (AEs) in dogs diagnosed with insulinoma and receiving toceranib.

Results: Records for 30 dogs diagnosed with insulinoma and having received toceranib were identified from a medical record search of five university and eight referral hospitals. The median progression-free interval and overall survival time were 561 days (95% confidence interval (CI): [246, 727 days]) and 656 days (95% CI: [310, 1045 days]), respectively. Of the dogs for which the canine Response evaluation criteria for solid tumours tool could be applied, the majority (66.7%) showed either a complete response, partial response or stable disease. Time to clinical progression was associated with prior intervention and type of veterinary practice. Larger dogs were at increased risk for disease progression and death. No novel AEs were reported.

Conclusions: Most dogs diagnosed with insulinoma and receiving toceranib appeared to have a clinical benefit. Randomised, prospective studies are needed to better elucidate and objectively quantify the potential effect and survival benefit of toceranib therapy for management of insulinoma in dogs.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Estimated Kaplan–Meier survival curve for median overall progression‐free interval for 30 dogs with insulinoma treated with toceranib. In absence of documentation of progressive disease, disease progression was considered not observed for 10 dogs, up until the last veterinary visit and the progression‐free interval was right‐censored for these cases
FIGURE 2
FIGURE 2
Estimated Kaplan–Meier survival curve for median overall survival time for 30 dogs with insulinoma treated with toceranib. In the absence of a death record, the overall survival time was right‐censored for nine dogs that were alive and still receiving toceranib at the time of last assessment
See this image and copyright information in PMC

References

    1. Goutal CM, Burgmann BL, Ryan KA. Insulinoma in dogs: a review. J Am Anim Hosp Assoc. 2012;48:151–63. - PubMed
    1. Lunn KF, Boston SE. Tumours of the endocrine system. In: Vail DM, Thamm DH, Liptak JM, editors. Withrow and MacEwen's small animal clinical oncology. 6th ed. St. Louis, MO, USA: Elsevier; 2013. p. 582–4.
    1. Nelson RW. Beta cell neoplasia: insulinoma. In: Feldman EC, Nelson RW, Reusch C, Scott‐Moncrieff JC, Behrend E, editors. Canine and feline endocrinology. 4th ed. St. Louis, MO, USA: Elsevier; 2015. p. 348–76.
    1. Caywood DD, Klausner JS, O'Leary TP, Withrow SJ, Richardson RC, Harvey HJ et al. Pancreatic insulin‐secreting neoplasms: clinical, diagnostic, and prognostic features in 73 dogs. J Am Anim Hosp Assoc. 1988;24:577–84.
    1. Kruth SA, Feldman EC, Kennedy PC. Insulin‐secreting islet cell tumours: establishing a diagnosis and the clinical course for 25 dogs. J Am Vet Med Assoc. 1982;181:54–8. - PubMed